HomeCompareRVNC vs EQR

RVNC vs EQR: Dividend Comparison 2026

RVNC yields 54.79% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RVNC wins by $455.3K in total portfolio value
10 years
RVNC
RVNC
● Live price
54.79%
Share price
$3.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$503.1K
Annual income
$109,600.15
Full RVNC calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — RVNC vs EQR

📍 RVNC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVNCEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVNC + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RVNC pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVNC
Annual income on $10K today (after 15% tax)
$4,657.53/yr
After 10yr DRIP, annual income (after tax)
$93,160.13/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, RVNC beats the other by $88,505.86/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVNC + EQR for your $10,000?

RVNC: 50%EQR: 50%
100% EQR50/50100% RVNC
Portfolio after 10yr
$275.4K
Annual income
$57,537.87/yr
Blended yield
20.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

RVNC
Analyst Ratings
10
Buy
12
Hold
Consensus: Hold
Price Target
$20.78
+469.3% upside vs current
Range: $6.66 — $37.00
Altman Z
-6.3
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVNC buys
0
EQR buys
0
No recent congressional trades found for RVNC or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVNCEQR
Forward yield54.79%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$503.1K$47.8K
Annual income after 10y$109,600.15$5,475.61
Total dividends collected$409.6K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$20.78$70.35

Year-by-year: RVNC vs EQR ($10,000, DRIP)

YearRVNC PortfolioRVNC Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$16,179$5,479.45$11,380$679.82+$4.8KRVNC
2$25,597$8,285.47$13,014$837.25+$12.6KRVNC
3$39,640$12,250.87$14,961$1,036.20+$24.7KRVNC
4$60,146$17,730.52$17,297$1,289.22+$42.8KRVNC
5$89,498$25,142.31$20,121$1,613.15+$69.4KRVNC
6$130,728$34,964.84$23,561$2,030.84+$107.2KRVNC
7$187,610$47,731.17$27,783$2,573.54+$159.8KRVNC
8$264,761$64,018.61$33,013$3,284.39+$231.7KRVNC
9$367,729$84,434.73$39,547$4,223.51+$328.2KRVNC
10$503,070$109,600.15$47,791$5,475.61+$455.3KRVNC

RVNC vs EQR: Complete Analysis 2026

RVNCStock

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Full RVNC Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this RVNC vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVNC vs SCHDRVNC vs JEPIRVNC vs ORVNC vs KORVNC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.